Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
Public ClinicalTrials.gov record NCT01482767. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Hepatitis C virus (HCV) infection is a leading cause of death and illness in people with HIV-1. At the time the study was designed, the standard treatment for people with HIV-1 and HCV coinfection included two drugs: pegylated-interferon alfa 2b (PEG-IFN) and ribavirin (RBV). The purpose of this study was to evaluate the effectiveness of giving boceprevir (BOC) together with standard treatment in treating HCV infection in people with HIV-1 and HCV coinfection.
Study identification
- NCT ID
- NCT01482767
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 262 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2012
- Primary completion
- Mar 31, 2015
- Completion
- Mar 31, 2015
- Last update posted
- Nov 3, 2021
2012 – 2015
United States locations
- U.S. sites
- 42
- U.S. states
- 20
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama CRS | Birmingham | Alabama | 35294 | — |
| University of Southern California CRS | Los Angeles | California | 90033-1079 | — |
| UCLA CARE Center CRS | Los Angeles | California | 90035 | — |
| Stanford AIDS Clinical Trials Unit CRS | Palo Alto | California | 94304-5350 | — |
| UCSD Antiviral Research Center CRS | San Diego | California | 92103 | — |
| Ucsf Hiv/Aids Crs | San Francisco | California | 94110 | — |
| Harbor-UCLA CRS | Torrance | California | 90502 | — |
| University of Colorado Hospital CRS | Aurora | Colorado | 80045 | — |
| Denver Public Health CRS | Denver | Colorado | 80204 | — |
| Georgetown University CRS (GU CRS) | Washington D.C. | District of Columbia | 20007 | — |
| The Ponce de Leon Center CRS | Atlanta | Georgia | 30308-2012 | — |
| Northwestern University CRS | Chicago | Illinois | 60611 | — |
| Rush University CRS | Chicago | Illinois | 60612 | — |
| IHV Baltimore Treatment CRS | Baltimore | Maryland | 21201 | — |
| Johns Hopkins University CRS | Baltimore | Maryland | 21205 | — |
| Massachusetts General Hospital CRS (MGH CRS) | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS | Boston | Massachusetts | 02115 | — |
| Bmc Actg Crs | Boston | Massachusetts | 02118 | — |
| Wayne State Univ. CRS | Detroit | Michigan | 48201 | — |
| Henry Ford Hosp. CRS | Detroit | Michigan | 48202 | — |
| Washington University Therapeutics (WT) CRS | St Louis | Missouri | 63110-1010 | — |
| Cooper Univ. Hosp. CRS | Camden | New Jersey | 08103 | — |
| New Jersey Medical School Clinical Research Center CRS | Newark | New Jersey | 07103 | — |
| Weill Cornell Chelsea CRS | New York | New York | 10011 | — |
| Columbia P&S CRS | New York | New York | 10032-3732 | — |
| Weill Cornell Uptown CRS | New York | New York | 10065 | — |
| University of Rochester Adult HIV Therapeutic Strategies Network CRS | Rochester | New York | 14642 | — |
| Bronx-Lebanon Hosp. Ctr. CRS | The Bronx | New York | 10457 | — |
| Chapel Hill CRS | Chapel Hill | North Carolina | 27599 | — |
| Duke Univ. Med. Ctr. Adult CRS | Durham | North Carolina | 27710 | — |
| Cincinnati Clinical Research Site | Cincinnati | Ohio | 45219 | — |
| Case Clinical Research Site | Cleveland | Ohio | 44106 | — |
| MetroHealth CRS | Cleveland | Ohio | 44109 | — |
| Ohio State University CRS | Columbus | Ohio | 43210 | — |
| Penn Therapeutics, CRS | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh CRS | Pittsburgh | Pennsylvania | 15213 | — |
| The Miriam Hospital Clinical Research Site (TMH CRS) CRS | Providence | Rhode Island | 02906 | — |
| Vanderbilt Therapeutics (VT) CRS | Nashville | Tennessee | 37204 | — |
| Trinity Health and Wellness Center CRS | Dallas | Texas | 75208 | — |
| Houston AIDS Research Team CRS | Houston | Texas | 77030 | — |
| Virginia Commonwealth University CRS | Richmond | Virginia | 23298 | — |
| University of Washington AIDS CRS | Seattle | Washington | 98104-9929 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01482767, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2021 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01482767 live on ClinicalTrials.gov.